Original Article

Effects of Respiratory Syncytial Virus Infection in Infancy on Asthma and Respiratory Allergy in 6-Year-Old Children

Authors: Panagiota Kitsantas, PhD, Lavanya Nirmalraj, MBBS, MS

Abstract

Objective: The purpose of this study was to examine the association between respiratory syncytial virus (RSV) infection in early infancy and health conditions such as asthma and respiratory allergies at 6 years of age in a cohort of US children born at term with no medical issues at birth.

Methods: Data (1542 records) from the Infant Feeding Practices Study II and the Year Six Follow-Up study were used in the analysis. Descriptive statistics and logistic regression were conducted to estimate the magnitude and direction of potential associations between children’s health conditions such as asthma, hay fever, or respiratory allergy, and RSV infection during infancy.

Results: A substantial proportion of children with RSV infection in infancy were reported to have developed asthma (10.3%) and hay fever or respiratory allergy (9.4%) by 6 years of age. Analyses revealed that children with RSV infection in infancy were more likely to develop asthma (odds ratio 1.99, 95% confidence interval 1.06–3.74), and hay fever or respiratory allergy (odds ratio 2.13, 95% confidence interval 1.28–3.57) by 6 years of age. In addition, the risk of developing asthma and hay fever or respiratory allergy by 6 years of age increased considerably with a family history of these conditions.

Conclusions: Our findings support the need for understanding and monitoring the long-term health outcomes of RSV infection in infancy. Appropriate prevention and treatment measures for RSV infection during infancy may reduce the incidence of associated long-term adverse health outcomes. Knowledge of the long-term complications of RSV infection in infancy, such as asthma, hay fever, or respiratory allergy, can aid in the prevention and better management of these health conditions.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-598.
 
2. Taussig LM, Holberg CJ, Wright AL. Prospective study of wheezing during the first three years of life. Am Rev Respir Dis 1993;147:A375.
 
3. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161:1501-1507.
 
4. Henderson J, Hilliard TN, Sherriff A, et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 2005;16:386-392.
 
5. American Academy of Pediatrics Committee on Infectious Diseases American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415-420.
 
6. Homaira N, Rawlinson W, Snelling TL, et al. Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: a real-world perspective. Int J Pediatr 2014;2014:571609.
 
7. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-86.
 
8. Prescott WA, Jr Doloresco F, Brown J, et al. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010;28:279-293.
 
9. Chadha AD, Bao W, Holloway J, et al. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009. South Med J 2012;105:399-404.
 
10. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011;30:510-517.
 
11. Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries. Infect Dis Ther 2016;5:271-298.
 
12. Centers for Disease Control and Prevention. Breastfeeding. Questionnaires: breastfeeding and infant feeding practices. Infant Feeding Practices Study II and its Year Six Follow-Up. https://www.cdc.gov/breastfeeding/data/ifps/questionnaires.htm. Published December 1, 2017. Accessed August 26, 2018.
 
13. Fein SB, Labiner-Wolfe J, Shealy KR, et al. Infant Feeding Practices Study II: study methods. Pediatrics 2008;122(suppl 2):S28-S35.
 
14. Fein SB, Li R, Chen J, et al. Methods for the Year 6 Follow-Up study of children in the Infant Feeding Practices Study II. Pediatrics 2014;134(suppl 1):S4-S12.
 
15. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-546.
 
16. Wu P, Dupont WD, Griffin MR, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med 2008;178:1123-1129.
 
17. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003;22(suppl 2):S76-S82.
 
18. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791-1799.